The short answer on whether you qualify

Two criteria, assessed in sequence, determine whether ChondroFiller™ injectable scaffold is worth exploring — and neither of them is how much pain you are in.

The first gate is prior conservative treatment: physiotherapy, activity modification, and where appropriate, injection therapies such as corticosteroid or hyaluronic acid. The second is imaging confirmation of cartilage damage on MRI. If both apply, defect-specific assessment begins.

Two misconceptions frequently stop patients from seeking assessment at all. The first is that you must be in severe, constant pain to qualify. Structural evidence of damage — not pain intensity — is what drives candidacy. Moderate, intermittent discomfort does not exclude you if the MRI findings are there.

The second misconception is that a 'bone on bone' description from a previous X-ray is an automatic no. For the injectable collagen scaffold pathway, which coats the entire cartilage surface rather than targeting a single bounded defect, this is not the case. There is also no strict upper age limit; patients well into their sixties and seventies are routinely assessed.

The sections below explain how defect grade, size, and joint mechanics factor into the full picture.

The two gateway criteria every assessment uses

Conservative management failure is the first gate — and 'failure' has a specific meaning in this context. Assessment typically requires that physiotherapy and load modification have been tried with inadequate relief, and that at least one relevant injection therapy (such as a corticosteroid or hyaluronic acid injection) has been attempted where clinically appropriate. The purpose of this gate is not bureaucratic: it confirms that the joint has had a fair opportunity to respond to less interventional approaches before a regenerative scaffold is considered.

Once that is established, the second gate opens: MRI-confirmed structural damage. Clinical symptoms — stiffness, swelling, activity-related pain — are informative but not sufficient on their own. An MRI provides direct evidence of cartilage integrity, defect location, depth of damage relative to the underlying bone, and the condition of surrounding tissue. This structural map is what the assessment process works from, not a symptom score.

Within that MRI report, grading using the Outerbridge (ICRS) scale identifies how much thickness has been lost. The injectable scaffold pathway is most relevant at Grade III or IV — classifications that indicate substantial or full-thickness cartilage loss in a focal area. The next section addresses what those grades mean in practice and how lesion size factors into the triage.

Neither gate alone is sufficient. Both must be satisfied before defect-specific assessment begins — making ChondroFiller™ injection a logical next step after conservative care has been fully optimised, rather than a first-line option.

Defect grade, size, and what 'focal' means in practice

Grade III means at least half the cartilage thickness is gone; Grade IV means the damage has reached the subchondral bone beneath. Both fall within the clinical indication for the injectable collagen scaffold pathway, building on what the grading scale identifies.

What matters alongside grade is morphology. The lesion must be focal — contained within a defined boundary, surrounded by cartilage tissue that is broadly intact. This is the distinction that often confuses patients: diffuse thinning spread across a joint compartment behaves differently from a discrete area of deep loss. The focal defect pathway is designed for the latter, not for generalised cartilage wear across a whole joint surface.

Size thresholds come into play once grade and morphology are confirmed. Standard clinical use targets focal lesions up to approximately 3 cm²; the device's CE-mark extends this upper boundary to around 6 cm². That broader ceiling matters in practice, because microfracture — one of the established surgical alternatives for focal cartilage repair — is generally considered suitable only for lesions under approximately 2–4 cm². Where defect size has previously been cited as a reason to defer surgical options, the injectable scaffold pathway may still fall within the eligible range.

The outpatient, ultrasound-guided injection form of ChondroFiller™ operates on a different basis entirely. Rather than targeting a single bounded defect, it is applied across the full cartilage surface as an additive cushion — a top-down protective layer rather than a structural rebuild from the base of one defect upward. This mechanism means the focal size gate described above does not apply to this pathway. Individual assessment is still required, but the selection logic differs from the focal defect route.

Factors that can reduce or complicate suitability

Beyond the gateway criteria, assessment looks for conditions that could compromise how well a collagen scaffold performs — even in a joint that meets the grade and size thresholds.

The single factor most consistently associated with poorer outcomes is untreated mechanical instability. If ligamentous laxity or a significant meniscal deficiency has altered how load moves through the joint, the biological environment for a new scaffold is already compromised. Addressing instability — or at least accounting for it in the treatment plan — is typically a prerequisite rather than an optional step.

Significant malalignment sits alongside this concern. Chronic overloading of a treated area, whether from varus or valgus deformity, works against integration over the 6–12 month regeneration window. In some cases, offloading strategies or alignment correction may be considered in parallel.

Advanced, end-stage osteoarthritis affecting the joint broadly — rather than a contained focal site — reduces suitability for the structural regenerative pathway. The CE-mark indication for focal defects does not extend to generalised end-stage wear. That said, the outpatient injectable form, which functions as a surface cushion across the whole cartilage, may still offer palliative benefit in this group; individual assessment determines which pathway, if any, is appropriate.

Some clinical contraindications — including known sensitivity to collagen components, active joint infection, or active inflammatory arthropathy — require direct discussion at consultation, where a full medical history can be reviewed. None of the factors above represents an automatic disqualification; each shifts the conversation toward individual clinical evaluation rather than closing it.

How the four-dimension framework shapes the assessment

Behind the numerical thresholds lies a more nuanced clinical process — one that assesses four dimensions simultaneously rather than running through a checklist and stopping at the first pass or fail.

The four areas are: mechanics (how load moves through the joint, and whether its distribution would support or undermine a scaffold); chemistry (the biological environment inside the joint — inflammatory activity, fluid composition, cellular signalling); biology (the condition of the surrounding tissue and the joint's remaining regenerative capacity); and timing (how far the wear process has advanced, and whether earlier or later in that progression the patient is presenting).

What this means in practice is that two patients with near-identical imaging may be routed toward different care options. The mechanics of one joint may favour the injectable scaffold pathway; the same structural appearance in a joint with significant malalignment may prompt a different sequence. Assessment is individual, not algorithmic.

This four-dimension lens also explains where ChondroFiller™ injectable scaffold occupies a position that older binary treatment ladders did not account for well. Conventional thinking tended to split patients into those with defects small enough for microfracture and those with damage too extensive for any joint-preserving approach. The injectable scaffold pathway sits between — and sometimes outside — those categories, relevant to patients who do not fit neatly into either group.

The timing dimension deserves particular attention: progression matters. Where the surrounding cartilage retains reasonable integrity, the biological environment is typically more favourable. Earlier assessment, before wear becomes generalised, generally offers more options — though individual assessment remains essential at any stage.

What assessment involves and what to expect if you proceed

Attending an assessment well-prepared makes a meaningful difference. Bringing any existing MRI — ideally taken within the past two to three years — allows the clinician to review defect location, depth, and surrounding cartilage integrity from the outset. Where no recent imaging is available, a scan can usually be arranged beforehand. Clinical history, previous treatments, and any biomechanical findings from physiotherapy or prior consultations all form part of the picture.

If assessment confirms suitability, the injectable collagen scaffold is placed under ultrasound guidance at an outpatient appointment. There is no theatre admission and no general anaesthetic on the injection pathway — patients typically leave the same day.

Cartilage regeneration is a slow biological process, and realistic expectations are part of any honest candidacy discussion. Published series suggest structural improvement develops over a period of approximately 6–12 months as the scaffold integrates and host cells mature within it. Functional changes may be noticed before imaging confirms fill; some patients experience earlier symptomatic benefit while the tissue is still forming.

In terms of published outcomes, series of over 19,000 cases internationally report meaningful improvements in functional knee and hip scores at 12 months, alongside MRI-measured integration scores in the moderate-to-good range. These figures reflect population-level data from published clinical series — they describe what evidence has recorded, not what any individual should expect.

For patients comparing pathways, the injectable route offers a single-stage, outpatient option with a low reported complication rate in the published literature — relevant context when weighing it against multi-stage surgical alternatives.

If the criteria covered in this article broadly match your situation, the AMSK assessment form is the appropriate starting point for an individual clinical review.